Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Deals  ·  Weekly Digest - 01 November to 07 November 2025
IntoCell and Xcellon Biologics partner to expand access to next-generation ADC technologies

Weekly Digest – November 2025 Weekly Digest – November 2025 31 October 2025: IntoCell and Xcellon Biologics partner to expand access to next-generation ADC technologies Xcellon Biologics, a leading ADC-focused CDMO, has entered into a partnership with IntoCell Inc. to […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 01 November to 07 November 2025
Ajinomoto Inc enters licensing agreement with Astellas Pharma for biopharmaceutical development and manufacturing technology

Weekly Digest – November 2025 Weekly Digest – November 2025 31 October 2025: Ajinomoto Inc enters licensing agreement with Astellas Pharma for biopharmaceutical development and manufacturing technology Ajinomoto Co., Inc. has entered into a licensing agreement with Astellas Pharma Inc. […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 25 October to 31 October 2025
Enhertu approved in Canada as the first and only HER2-directed therapy for patients with HR-positive HER2-low or HER2-ultralow metastatic breast cancer, following disease progression after one or more endocrine therapies

Weekly Digest – October 2025 Weekly Digest – October 2025 29 October 2025: Enhertu approved in Canada as the first and only HER2-directed therapy for patients with HR-positive HER2-low or HER2-ultralow metastatic breast cancer, following disease progression after one or […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 25 October to 31 October 2025
Marketing approval obtained in China for Meiyouheng (Becotatug Vedotin injection)

Weekly Digest – October 2025 Weekly Digest – October 2025 30 October 2025: Marketing approval obtained in China for Meiyouheng (Becotatug Vedotin injection) The NMPA has granted marketing approval in China for Becotatug Vedotin injection, an innovative EGFR-targeted ADC developed […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 25 October to 31 October 2025
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives orphan drug designation in the EU

Weekly Digest – October 2025 Weekly Digest – October 2025 28 October 2025: GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives orphan drug designation in the EU GSK’s B7-H3-targeted ADC, GSK5764227 (GSK’227), has received Orphan Drug Designation (ODD) from the European Medicines […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 25 October to 31 October 2025
Alphamab Oncology announces biparatopic HER2-targeting ADC JSKN003 was granted fast track designation by FDA for the treatment of PROC

Weekly Digest – October 2025 Weekly Digest – October 2025 28 October 2025: Alphamab Oncology announces biparatopic HER2-targeting ADC JSKN003 was granted fast track designation by FDA for the treatment of PROC Alphamab Oncology’s biparatopic HER2-targeting ADC, JSKN003, has received […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 25 October to 31 October 2025
Cellectar Biosciences receives rare pediatric disease designation from U.S. FDA for Iopofosine I 131 in relapsed or refractory pediatric high-grade glioma

Weekly Digest – October 2025 Weekly Digest – October 2025 27 October 2025: Cellectar Biosciences receives rare pediatric disease designation from U.S. FDA for Iopofosine I 131 in relapsed or refractory pediatric high-grade glioma Cellectar Biosciences received Rare Pediatric Disease […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 25 October to 31 October 2025
GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer

Weekly Digest – October 2025 Weekly Digest – October 2025 27 October 2025: GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer GSK secured exclusive global rights from Syndivia to develop and commercialize a preclinical antibody-drug […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 18 October to 24 October 2025
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

Weekly Digest – October 2025 Weekly Digest – October 2025 23 October 2025: Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma The US FDA has approved Blenrep (Belantamab mafodotin) in combination with bortezomib and dexamethasone […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 18 October to 24 October 2025
Core product Trastuzumab botidotin approved for marketing by the NMPA for 2L+ HER2+ breast cancer

Weekly Digest – October 2025 Weekly Digest – October 2025 17 October 2025: Core product Trastuzumab botidotin approved for marketing by the NMPA for 2L+ HER2+ breast cancer Sichuan Kelun-Biotech’s core product trastuzumab botidotin (A166) received marketing approval from China’s […]

by Sandhya Ramalingam

Continue Reading
« First‹ Previous303132333435363738Next ›Last »
Page 34 of 63


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id